Company profile
Oncobit AG
To offer personalized therapies, diagnostics must keep pace to provide the necessary information. Oncobit is a MedTech spin-off from the University of Zurich, developing critical precision diagnostic and monitoring solutions to enable the cancer treatment of the future. A unique combination of technical know-how, proprietary software and close clinical collaborations, allows us to bring more comprehensive and more sensitive tests to the clinic to improve patient care and outcome. With an initial focus on melanoma, our approach is easily expandable to other cancer types in the future. We are collaborating with leading cancer center in Europe and the US to achieve broad acceptance by the medical community.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
